{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:41:00Z","timestamp":1761176460598,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) is a life-limiting autosomal recessive disease often treated with triple CFTR modulator therapy (elexacaftor\/tezacaftor\/ivacaftor, ETI). Sleep disturbances are common in people with CF (pwCF). This study evaluated the Sleepiz One+, a non-contact radar-based biomotion sensor, for monitoring respiratory rate, heart rate, apnea-hypopnea index (AHI), and sleep quality in pwCF with \u2265\u20091 F508del allele during ETI therapy. The device\u2019s suitability for home monitoring of therapy success was also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a six-month observational study, 58 adult pwCF (2908 recordings) used the Sleepiz One\u2009+\u2009at home to collect longitudinal data on respiratory and sleep parameters during ETI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant reductions in respiratory rate and time in bed were observed after starting ETI, with respiratory rate decreases detectable within 1\u20135 days. Short-term respiratory rate increases corresponded with infections verified by medical records. Heart rate decreased non-significantly, and sleep efficiency improved modestly. AHI slightly decreased overall but increased in some patients, possibly linked to ETI-related weight gain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sleepiz One\u2009+\u2009reliably tracked respiratory and sleep changes during ETI therapy in adult pwCF. It shows promise for early infection detection via respiratory rate monitoring, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11325-025-03451-8","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:01:38Z","timestamp":1758636098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-6670","authenticated-orcid":false,"given":"Sarah","family":"Dietz-Terjung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svenja","family":"Stra\u00dfburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sch\u00f6bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Ezzahra","family":"Gahbiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivagurunathan","family":"Sutharsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Welsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"3451_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373:1891\u20131904","journal-title":"Lancet"},{"key":"3451_CR2","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS (2016) Cystic fibrosis. Lancet 388:2519\u20132531","journal-title":"Lancet"},{"key":"3451_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H et al (2020) The future of cystic fibrosis care: a global perspective. Lancet Respir Med 8:65\u2013124","journal-title":"Lancet Respir Med"},{"key":"3451_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1712984","volume":"253","author":"MP Anderson","year":"1991","unstructured":"Anderson MP, Gregory RJ, Thompson S et al (1991) Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253:202\u2013205","journal-title":"Science"},{"key":"3451_CR5","unstructured":"factsheet_mukoviszidose.pdf"},{"key":"3451_CR6","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG et al (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365:1663\u20131672","journal-title":"N Engl J Med"},{"key":"3451_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","volume":"201","author":"MA Mall","year":"2020","unstructured":"Mall MA, Mayer-Hamblett N, Rowe SM (2020) Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am J Respir Crit Care Med 201:1193\u20131208","journal-title":"Am J Respir Crit Care Med"},{"key":"3451_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L et al (2018) VX-445\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med 379:1612\u20131620","journal-title":"N Engl J Med"},{"key":"3451_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","volume":"77","author":"JR Riordan","year":"2008","unstructured":"Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77:701\u2013726","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"3451_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","volume":"10","author":"S Sutharsan","year":"2022","unstructured":"Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA, VX18-445-109 study group (2022) Efficacy and safety of Elexacaftor plus Tezacaftor plus Ivacaftor versus Tezacaftor plus Ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med 10(3):267\u2013277. https:\/\/doi.org\/10.1016\/S2213-2600(21)00454-9Epub 2021 Dec 20. PMID: 34942085","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3451_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jcf.2021.10.005","volume":"21","author":"ST Pallenberg","year":"2022","unstructured":"Pallenberg ST, Junge S, Ringshausen FC, Sauer-Heilborn A, Hansen G, Dittrich AM, T\u00fcmmler B, Nietert M (2022) CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the \u03b2-adrenergic sweat rate assay. J Cyst Fibros 21(3):442\u2013447 Epub 2021 Oct 29. PMID: 34756683","journal-title":"J Cyst Fibros"},{"issue":"2","key":"3451_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen MC, Begnel L, Wallendorf M, Litvin M (2022) Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 21(2):265\u2013271. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.012Epub 2021 Dec 1. PMID: 34862121; PMCID: PMC9999463","journal-title":"J Cyst Fibros"},{"issue":"5","key":"3451_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2022","unstructured":"Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM (2022) PROMISE study group. clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial. Am J Respir Crit Care Med 205(5):529\u2013539. https:\/\/doi.org\/10.1164\/rccm.202108-1986OCPMID: 34784492; PMCID: PMC8906485","journal-title":"Am J Respir Crit Care Med"},{"key":"3451_CR14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1159\/000524773","volume":"101","author":"M Welsner","year":"2022","unstructured":"Welsner M, Schulte T, Dietz-Terjung S, Weinreich G, Stehling F, Taube C et al (2022) Effect of triple combination CFTR modulator therapy on sleep in adult patients with cystic fibrosis. Respiration 101:766\u2013774","journal-title":"Respiration"},{"issue":"4","key":"3451_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s11325-011-0599-5","volume":"16","author":"C Perin","year":"2012","unstructured":"Perin C, Fagondes SC, Casarotto FC, Casarotto FC, Pinotti AFF, Menna Barreto SS et al (2012) Sleep findings and predictors of sleep desaturation in adult cystic fibrosis patients. Sleep Breath 16(4):1041\u20131048","journal-title":"Sleep Breath"},{"issue":"11","key":"3451_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/archdischild-2011-300440","volume":"97","author":"B Fauroux","year":"2012","unstructured":"19, Fauroux B, Pepin J-L, Boelle P-Y, Cracowski C, Murris-Espin M, Nove-Josserand R et al (2012) Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Arch Dis Child 97(11):960\u2013966","journal-title":"Arch Dis Child"},{"key":"3451_CR17","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.smrv.2020.101279","volume":"51","author":"J Reiter","year":"2020","unstructured":"Reiter J, Gileles-Hillel A, Cohen-Cymberknoh M, Rosen D, Kerem E, Gozal D, Forno E (2020) Sleep disorders in cystic fibrosis: A systematic review and meta-analysis. Sleep Med Rev 51:101279. https:\/\/doi.org\/10.1016\/j.smrv.2020.101279Epub 2020 Feb 19. PMID: 32145647; PMCID: PMC7198356","journal-title":"Sleep Med Rev"},{"key":"3451_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.rmed.2012.06.010","volume":"106","author":"A Bouka","year":"2012","unstructured":"Bouka A, Tiede H, Liebich L, Dumitrascu R, Hecker C, Reichenberger F et al (2012) Quality of life in clinically stable adult cystic fibrosis out-patients: associations with daytime sleepiness and sleep quality. Respir Med 106:1244\u20131249","journal-title":"Respir Med"},{"key":"3451_CR19","doi-asserted-by":"crossref","unstructured":"Milross MA, Piper AJ, Norman M, Dobbin CJ, Grunstein RR, Sullivan CE et al (2002) Subjective sleep quality in cystic fibrosis. Sleep Med 3(9)","DOI":"10.1016\/S1389-9457(01)00157-5"},{"issue":"8","key":"3451_CR20","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ppul.25462","volume":"57","author":"J Reiter","year":"2022","unstructured":"Reiter J, Breuer O, Cohen-Cymberknoh M, Forno E, Gileles-Hillel A (2022) Sleep in children with cystic fibrosis: more under the covers. Pediatr Pulmonol 57(8):1944\u20131951","journal-title":"Pediatr Pulmonol"},{"key":"3451_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jpeds.2016.11.069","volume":"182","author":"M Vandeleur","year":"2017","unstructured":"Vandeleur M, Walter LM, Armstrong DS, Robinson P, Nixon GM, Horne RS (2017) How well do children with cystic fibrosis sleep? An actigraphic and questionnaire-based study. J Pediatr 182:170\u2013176","journal-title":"J Pediatr"},{"key":"3451_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.rmed.2019.03.022","volume":"151","author":"M Cohen-Cymberknoh","year":"2019","unstructured":"Cohen-Cymberknoh M, Atia O, Gileles-Hillel A, Kerem E, Reiter J (2019) Sleep disorders in patients with primary ciliary dyskinesia, cystic fibrosis with and without pancreatic insufficiency. Respir Med 151:96\u2013101","journal-title":"Respir Med"},{"issue":"4","key":"3451_CR23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ppul.26318","volume":"58","author":"KS McCoy","year":"2023","unstructured":"McCoy KS, Blind J, Johnson T, Olson P, Raterman L, Bai S, Eisner M, Sheikh SI, Druhan S, Young C, Pasley K (2023) Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis. Pediatr Pulmonol 58(4):1178\u20131184. https:\/\/doi.org\/10.1002\/ppul.26318Epub 2023 Jan 27. PMID: 36650567","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"3451_CR24","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1038\/s41598-023-30171-4","volume":"13","author":"B Bujan","year":"2023","unstructured":"Bujan B, Fischer T, Dietz-Terjung S, Bauerfeind A, Jedrysiak P, Gro\u00dfe Sundrup M, Hamann J, Sch\u00f6bel C (2023) Clinical validation of a contactless respiration rate monitor. Sci Rep 13(1):3480. https:\/\/doi.org\/10.1038\/s41598-023-30171-4PMID: 36859403; PMCID: PMC9975830","journal-title":"Sci Rep"},{"issue":"1","key":"3451_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12890-022-01855-w","volume":"22","author":"S Stra\u00dfburg","year":"2022","unstructured":"Stra\u00dfburg S, Linker CM, Brato S, Sch\u00f6bel C, Taube C, G\u00f6tze J, Stehling F, Sutharsan S, Welsner M, Weinreich G (2022) Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system. BMC Pulm Med 22(1):59. https:\/\/doi.org\/10.1186\/s12890-022-01855-wPMID: 35148739; PMCID: PMC8832687","journal-title":"BMC Pulm Med"},{"issue":"4","key":"3451_CR26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s11325-024-03057-6","volume":"28","author":"JA Gross-Isselmann","year":"2024","unstructured":"Gross-Isselmann JA, Eggert T, Wildenauer A, Dietz-Terjung S, Grosse Sundrup M, Schoebel C (2024) Validation of the sleepiz One\u2009+\u2009as a radar-based sensor for contactless diagnosis of sleep apnea. Sleep Breath 28(4):1691\u20131699. https:\/\/doi.org\/10.1007\/s11325-024-03057-6Epub 2024 May 14. PMID: 38744804; PMCID: PMC11303430","journal-title":"Sleep Breath"},{"issue":"5","key":"3451_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","volume":"22","author":"D Proud","year":"2023","unstructured":"Proud D, Duckers J (2023) Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF. J Cyst Fibros 22(5):847\u2013850 Epub 2023 Jun 23. PMID: 37355345","journal-title":"J Cyst Fibros"},{"key":"3451_CR28","doi-asserted-by":"publisher","unstructured":"Gramegna A, Ruscica M, Leonardi G, Macchi C, Fichtner I, Putti G, Schianca MC, Terranova L, Alicandro G, Blasi F Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy. J Cyst Fibros. 2024 Dec 6:S1569-1993(24)01844-7. doi:https:\/\/doi.org\/10.1016\/j.jcf.2024.11.009. Epub ahead of print. PMID: 39645478","DOI":"10.1016\/j.jcf.2024.11.009"},{"issue":"6","key":"3451_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","volume":"22","author":"LR Caley","year":"2023","unstructured":"Caley LR, Jarosz-Griffiths HH, Smith L, Gale L, Barrett J, Kinsey L, Davey V, Nash M, Jones AM, Whitehouse JL, Shimmin D, Floto RA, White H, Peckham DG (2023) Body mass index and nutritional intake following elexacaftor\/tezacaftor\/ivacaftor modulator therapy in adults with cystic fibrosis. J Cyst Fibros 22(6):1002\u20131009 Epub 2023 Jul 6. PMID: 37422432","journal-title":"J Cyst Fibros"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-025-03451-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-025-03451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:12:39Z","timestamp":1761127959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-025-03451-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3451"],"URL":"https:\/\/doi.org\/10.1007\/s11325-025-03451-8","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"type":"print","value":"1520-9512"},{"type":"electronic","value":"1522-1709"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of the University Duisburg-Essen (19-8961-BO) and all procedures were performed in accordance with the Declaration of Helsinki. All patients have provided their written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.D.-T., S.S. (Svenja Stra\u00dfburg), T.S., F.E.G, J.O., M.W., G.W., and P.D. have no conflicts of interest to declare. S.S. (Sivagurunathan Sutharsan) received personal fees from Proteostasis Therapeutics, Novartis Pharma, Vertex Pharmaceuticals, Chiesi, and Teva outside of the submitted work; and grants from Galapagos, Proteostasis Therapeutics, Celtaxsys, Flatley, Vertex Pharmaceuticals, Teva, Chiesi, Boehringer Ingelheim, Corbus Pharmaceuticals, and Ionis Pharmaceuticals outside of the sub-mitted work. CS has received consulting\/speaking fees and research support from Astra Zeneca, Bayer, BerlinChemie, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Jazz Pharma, L\u00f6wen-stein Medical, Novartis, Philips Respironics, ResMed, and UCB. CT reports consulting fees paid to his institution from AstraZeneca, Novartis, Chiesi, and GSK; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events paid to his institution from AstraZeneca, Novartis, Chiesi and GSK; and an unpaid leadership or fiduciary role at the German Society of Allergy in the past 36 months.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}